Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CANbridge Acquires China Rights to Puma Cancer Candidate in $70 Million Deal

publication date: Feb 2, 2018

CANbridge Life Sciences of Beijing in-licensed Greater China rights to a breast cancer treatment from Puma Biotech of the US in a $70 million agreement. In July 2017, Nerlynx® (neratinib) was approved in the US for patients with early-stage HER2-positive breast cancer whose cancer recurs after treatment. CANbridge paid $30 million upfront for the China rights and will add up to $40 million in milestone payments, plus royalties. More details....

Stock Symbol: (NSDQ: PBYI)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.